Shore Capital's Everis merges with Hemostasis to deepen ENT portfolio
What's the deal? EverisDealroom has a profile for this one. Try Dealroom → Medical, a Shore Capital PartnersDealroom has a profile for this one. Try Dealroom →-backed medical device company focused on otolaryngology and head and neck surgery, has merged with HemostasisDealroom has a profile for this one. Try Dealroom →, a developer of advanced sinus dressings and surgical hemostats. Terms were not disclosed. The combined company will operate under the Everis Medical name, led by founder and chief executive officer Kevin McLeod.
What's the endgame? The deal extends Everis's reach across sinus and nasal surgery — from repair and reconstruction to hemostasis, postoperative healing, and infection management. Hemostasis adds chitosan-based sinus dressings and surgical hemostats to the platform.
Why now? The merger is Everis's sixth transaction since 2019. It follows the May 2026 purchase of Hood Laboratories, which added airway and thoracic devices to the Shore Capital-backed platform.
Who advised? Piper SandlerDealroom has a profile for this one. Try Dealroom → served as financial advisor and Fox RothschildDealroom has a profile for this one. Try Dealroom → as legal advisor to Hemostasis. Cain Brothers advised Shore Capital on the buy side, with DLA PiperDealroom has a profile for this one. Try Dealroom → as legal advisor to Everis and Shore Capital.
The signal: With terms undisclosed, strategic intent is clearer than deal scale. Everis is building a focused ENT platform through acquisitions rather than chasing a broader sector play.
Read more: themiddlemarket.com
Image credit: "ENT surgery in GH for mobile camp patients" by Bhakua, licensed under CC BY 2.0